about
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodiesTargeted immunotherapy for pediatric solid tumorsInhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticlesProtein glycosylation in cancers and its potential therapeutic applications in neuroblastomaPhase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.GD2 expression in breast cancer.NK cell-based immunotherapy for malignant diseases.Antibody recognition of cancer-related gangliosides and their mimics investigated using in silico site mapping.Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.Therapeutic targets for neuroblastomas.Estradiol represses the G(D3) synthase gene ST8SIA1 expression in human breast cancer cells by preventing NFκB binding to ST8SIA1 promoter.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.Neuroblastoma: developmental biology, cancer genomics and immunotherapy.Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISALigands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology.Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8Natural killer cells: role in local tumor growth and metastasisImmunotherapy targets in pediatric cancer.Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastomaOcular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322APotential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cellsThe biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).State of the art in anti-cancer mAbs.Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.Treatment of high-risk neuroblastoma with anti-GD2 antibodies.Neuroendocrine cancer vaccines in clinical trials.Virotherapy of neuroendocrine tumors.Nanomedicine as an innovative therapeutic strategy for pediatric cancer.Immune Therapy for Sarcomas.Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.Management of neuroblastoma: a study of first- and second-line chemotherapy responses, a single institution experience.Linker-free conjugation and specific cell targeting of antibody functionalized iron-oxide nanoparticles.Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.
P2860
Q21131216-67AB6D72-47DD-4E65-B1D9-C4852CCF3552Q26747703-2BC3B5A5-EE3F-49CC-8DF5-525F296E2677Q27301841-D4358118-E7F5-4D8C-BE0D-FBFC1D566700Q28069952-E147AE4E-08E8-4AFB-9B9B-C6C89B30D719Q33597441-FFB55A00-6AFA-4159-A7D9-7E432CD3BBDDQ33613772-8BEAC4C2-31E7-4D5C-B739-F7486C664723Q33761830-FA61A439-8526-4E4D-B1A5-38FD9E538C92Q33827433-A69063A6-C07D-4A50-9CB0-5AB895F00BA5Q34247281-6D51B8AB-8808-4DCC-AA1A-3EA9598EFFBCQ34389202-A8E6D2F7-B965-4FFD-9E04-9407805CAB18Q34560877-FE146538-14F5-4146-A818-8A085AC2B30AQ34693290-3605BDB6-5329-4CA2-840B-9D2A4A58FF66Q35031732-4908B25A-D1AA-40CE-ACD8-8248DE661396Q35146479-6997D69D-4B1B-4C05-A4C4-0F053088A2A9Q35283020-56A39369-47D5-49B1-862D-B4C49EC79408Q35381031-27D77174-9744-4748-B02F-09A71B8B252FQ35739810-6C0A26F0-65DF-4587-8329-386EE89BD8FBQ35860917-BCDE7532-3F20-4863-B254-D76D987C1281Q35905953-23177642-07A2-44B1-9859-98A75A56E597Q35971029-72C31AC3-91B7-4D0A-87FB-2921D1B45297Q36057459-DEC16E67-EAE0-4A72-B2C4-30C2C5ACF3C3Q36093931-CD15479A-966E-4DBC-82DA-BE50C349BB98Q36423660-11F6DBF1-B23C-4518-BFBC-C9DE5D6A84EFQ36821533-EA152293-697D-4329-AC64-F3AD8AEB4178Q37099383-087B60D5-5C3D-4FFF-9556-8BD8F2338E58Q37589671-86CC0E76-5FC0-4877-A13A-2E56BA6CE83AQ37655585-DD2F0CBA-7533-4072-A2CC-2926FD528532Q37706213-AB257F96-CF39-4B14-87D5-DDED9019D32BQ37725488-1AA9F4B2-A3F9-4D07-9671-91DE331FB53EQ37820755-BD125FAC-CA42-4AB5-963C-BA3BDB4FEC57Q37892589-8B760F43-3FAC-4D0E-A6C1-66263DD97947Q37989391-F933A1A7-CBB3-4681-A354-DF7C071AFE10Q38359099-6032DF88-3044-43F1-8EDA-72EACD73EDA6Q38742533-4FFCBC15-DF3E-4199-9B10-1A3E4FD89142Q38751090-92067337-D800-4077-B785-83736EE13EDDQ39539858-9415F955-C999-4ABE-A29B-23F504B3A58FQ39639490-83709033-C7B4-4474-9820-EC99A174D2C3Q40264175-AD07398E-B1E8-4D39-B512-39101D5ADDEDQ41962637-E1A3E443-CEA2-4C21-8DD8-D82CB48C3437Q42053371-52D7CF00-8C66-48AB-99D3-7AAC343CD701
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-GD2 antibody therapy for GD2-expressing tumors.
@en
Anti-GD2 antibody therapy for GD2-expressing tumors.
@nl
type
label
Anti-GD2 antibody therapy for GD2-expressing tumors.
@en
Anti-GD2 antibody therapy for GD2-expressing tumors.
@nl
prefLabel
Anti-GD2 antibody therapy for GD2-expressing tumors.
@en
Anti-GD2 antibody therapy for GD2-expressing tumors.
@nl
P2093
P2860
P1476
Anti-GD2 antibody therapy for GD2-expressing tumors.
@en
P2093
Fariba Navid
Raymond C Barfield
Victor M Santana
P2860
P304
P356
10.2174/156800910791054167
P577
2010-03-01T00:00:00Z